1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6AA2680C52240E955652579530048B19B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/internal-communication-types-frequency-medium-effectiveness?opendocument
18
19opendocument
2035.172.195.49
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Business Communications » Internal Communication Excellence

Internal Communication Excellence: Tactics Used by Biopharma Executives to Increase Organizational Effectiveness

ID: 5174


Features:

32 Data Graphics

450+ Metrics


Pages/Slides: 53


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Internal Communication Excellence: Tactics Used by Biopharma Executives to Increase Organizational Effectiveness"


STUDY OVERVIEW

Technological advances have dramatically increased the amount and frequency of communication in the pharmaceutical workplace - in particular Internal Communication. However, the diversity of communication tools, sources, and platforms makes it difficult to ascertain the preferred and most effective Internal Communication tactics and strategies within the pharmaceutical industry.

Best Practices, LLC conducted this research to identify the most effective Internal Communication tools and how employees within the biopharmaceutical industry best utilize various communication formats to achieve organizational objectives. Specifically, this study reviews the frequency and type of Internal Communications shared and received, and the type of work-related Internal Communications viewed and forwarded with mobile devices. The largest portion of the study focuses on the which communication mediums (voice mail, email, intranet, etc.) are most effective within pharma companies for various types of Internal Communications, including general, industry, product, strategy, vendor, training, performance and others. In addition, the study presents the most effective communication platforms for communicating with superiors, peers and subordinates when sharing information regarding projects, products, training, industry, and more.

Biopharma professionals who use and send Internal Communications can use this study to identify the preferred communication formats/platforms for a sharing a broad range of Internal Communications to achieve organizational success.

KEY TOPICS

  • Types and frequency of Internal Communication shared and received
  • Identify Internal Communication medium & preferences for array of message types
  • Measure Internal Communication Effectiveness
  • Voices from the Field

SAMPLE KEY METRICS
  • Most & Least Commonly used Medium for Internal Communication
  • Use of Mobile for Internal Communication
  • Preference vs. Effectiveness: Internal Communication Using Mobile
  • Effective Tools for general communication, industry information, case studies, product information, strategy guidance, vendor communication, training and more
  • Average Weekly Hours Spent on Internal Communications
  • Effective Tactic to Prioritize Communications
  • Percentage of Redundant Communications Received Internally

SAMPLE KEY FINDING
  • Effectively Tackle Internal Communication Using Type: Organizing emails by type (action required vs. informative) is the most effective method. However, pharmaceutical respondents then consider (1) the sender and (2) the content while non-pharmaceutical respondents utilize technology to consider importance.


METHODOLOGY
The benchmark class of participants includes total of 51 representatives from the biopharma sector. Qualitative and quantitative data for this report were collected through an online survey instrument.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Consulting; Banking; Financial Services; Insurance; Non-Profit; Chemical; Business; Professional Services; Manufacturing; Distribution; Transportation; Education; Market Research; Marketing; Public Relations; Architecture; Engineering; Communications; Aerospace; Automobile; Aviation; Computer Software; Telecommunications; Medical Device; Government; Military; Advertising; Defense; Science; Clinical Research


Companies Profiled:
Abbott; Sanofi Pasteur; Gardner Assocites; Target Point ltd; AllianceBernstein; The Aspen Institute; Economic Opportunities Program; Genentech/Roche; The Bluestar Group; AsiaConnect; The Gordon Group; General Products Corp.; Union National Bank; Zogenix; Hertz Corporation; Assessment & Information group; Jefferson Associates Inc; Pearson; Kadmon Pharmaceuticals; Barr Engineering; Kiernan Group; Inc.; Xanodyne Pharmaceuticals; Kimble Chase LLC; Bayer Corporation; MedPanel; Bee Tree Consulting; MESCO; ltd; Nationwide Financial; Biotest Pharmaceuticals; Omicron Canada Inc.; Wells Fargo; One Communications; Bosch Power Tools; Parallel Consulting; Bristow Group; Porsche Cars North Americq; Oracle; Prescience International; BT Conferencing; ProVeritas Management Consulting; Celgene Pte Ltd; Reliance Industries Limited; Johnson & Johnson; Royal Thai Air Force; CIT Group; Sales Channel Europe; Citibank; City of Houston; Pfizer; Commutateur; Corium International Inc.; Inspire Pharmaceuticals; Croda Inc; Deloitte; Quintiles; Eastwest Bank; Ethicon; Kimble Chase; Roche; Honeywell; Rockland Trust Company; KPMG; Sandoz; Cloud Currencies; HCA; Sanofi-Aventis; Lockheed Martin; Stryker; Grundfos Pumps Manufacturing Corp; Sunovion; Lundbeck; Fidelity Investments; Talecris; Genzyme; Thermo Fisher; Medtronic; Vertex Pharmaceuticals; Genentech; Vimta Labs; GlaxoSmithKline; Novartis; Olympus Corporation; Avaya; Astellas; AstraZeneca; Alcon; Bank of America; Baxter Healthcare; Becton Dickinson; Bell Canada; BioCentric; Cephalon; Countrywide Financial; Elan Corporation; EMD Serono; Exelixis

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.